C

    Corvus Pharmaceuticals Inc (CRVS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.04
    -0.12 (-0.85%)

    Market Cap: $1.19B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    -12.75%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.22 - $-0.18
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate Drift
    90d ago$-0.20+4.9%
    60d ago$-0.19+7.3%
    30d ago$-0.19+7.3%
    7d ago$-0.19+8.5%
    Current$-0.20
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.25
    Range$-0.28 - $-0.18
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.25---
    Sep 26EST
    		-$-0.20---
    Jun 26
    		$-0.19$-0.17-11.76%Miss-90.0%
    Mar 26
    		$-0.15$-0.15+0.00%Beat-7.1%
    Dec 25
    		$-0.15$-0.13-18.48%Miss-5.0%
    Sep 25
    		$-0.12$-0.13+7.69%Beat+80.0%
    Jun 25
    		$-0.10$-0.13+23.08%Beat-42.9%
    Mar 25
    		$-0.14$-0.12-16.67%Miss-16.7%
    Dec 24
    		$-0.14$-0.12-19.08%Miss-2.1%
    Sep 24
    		$-0.60$-0.12-400.00%Miss-400.0%
    Jun 24
    		$-0.07$-0.11+36.36%Beat+50.0%
    Mar 24
    		$-0.12$-0.13+7.69%Beat+29.4%
    Dec 23
    		$-0.14$-0.12-16.67%Miss+33.3%
    Sep 23
    		$-0.12$-0.12+0.00%Beat+62.5%
    Jun 23
    		$-0.14$-0.14+0.00%Beat+22.2%
    Mar 23
    		$-0.17$-0.17+0.00%Beat+5.6%
    Dec 22
    		$-0.21$-0.23+8.70%Beat-5.0%
    Sep 22
    		$-0.32$-0.14-128.57%Miss-33.3%
    Jun 22
    		$-0.18$-0.18+0.00%Beat+35.7%
    Mar 22
    		$-0.18$-0.15-20.00%Miss+47.1%
    Dec 21
    		$-0.20$-0.19-5.26%Miss+39.4%
    Sep 21
    		$-0.24$-0.24+0.00%Beat+27.3%
    Jun 21
    		$-0.28$-0.31+9.68%Beat+22.2%
    Mar 21
    		$-0.34$-0.31-9.68%Miss+22.7%
    Dec 20
    		$-0.33$-0.32-3.13%Miss+13.2%
    Sep 20
    		$-0.33$-0.22-50.00%Miss+10.8%
    Jun 20
    		$-0.36$-0.24-50.00%Miss+18.2%
    Mar 20
    		$-0.44$-0.40-10.00%Miss-10.0%
    Dec 19
    		$-0.38$-0.33-15.15%Miss-5.6%
    Sep 19
    		$-0.37$-0.43+13.95%Beat-2.8%
    Jun 19
    		$-0.44$-0.44+0.00%Beat-10.0%
    Mar 19
    		$-0.40$-0.48+16.67%Beat+36.5%
    Dec 18
    		$-0.36$-0.46+21.74%Beat+37.9%
    Sep 18
    		$-0.36$-0.49+26.53%Beat+41.9%
    Jun 18
    		$-0.40$-0.61+34.43%Beat+45.2%
    Mar 18
    		$-0.63$-0.77+18.18%Beat+20.3%
    Dec 17
    		$-0.58$-0.77+24.68%Beat-5.5%
    Sep 17
    		$-0.62$-0.84+26.19%Beat-21.6%
    Jun 17
    		$-0.73$-0.74+1.35%Beat-
    Mar 17
    		$-0.79$-0.77-2.60%Miss-
    Dec 16
    		$-0.55$-0.57+3.51%Beat-
    Sep 16
    		$-0.51$-0.45-13.33%Miss-

    Key Metrics

    Valuation
    P/E Ratio-23.02EV/EBITDA0.36x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-35.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio16.16xQuick Ratio16.16x
    Trading Statistics
    Beta0.87Avg Volume745.33K
    52-Week High$26.9552-Week Low$5.58

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.53
    SMA 20$14.47
    SMA 50$14.29
    SMA 200$13.68
    EMA 10$14.43
    EMA 20$14.39
    EMA 50$14.19
    EMA 200$12.87

    MACD

    Line: 0.09Signal: 0.16Hist: -0.07

    ADX

    ADX: 10.6+DI: 20.9-DI: 27.7

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down4.0
    PSAR$15.53

    Bollinger Bands

    Upper Band$15.45
    Lower Band$13.49
    %B Position1360%(Upper)
    Band Width0.28

    RSI (14-Day)

    Neutral
    46.5

    Momentum Oscillators

    Stoch %K33.1
    Stoch %D47.9
    Williams %R-83.6
    ROC (10d)-5.8%
    Momentum-0.87
    CCI (20d)-75.6
    MFI (14d)54.0

    Volatility Measures

    ATR (14d)$0.70(5.0%)
    StdDev (20d)0.49
    Hist Vol48.3%(High)

    Volume Flow

    VWAP$13.97
    OBV81.3M
    AD Line45.7M
    CMF (20d)0.042

    Volume Metrics

    Avg Vol (20d)753.6K
    Vol Ratio1.0x
    VWMA (20d)$14.47

    Pivot Points

    R3$15.14
    R2$14.87
    R1$14.52
    Pivot Point$14.24
    S1$13.89
    S2$13.62
    S3$13.27

    Advanced Oscillators

    TSI4.22
    Ultimate Osc45.3
    KST30.32

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$88,000$0$0$0$246,000$0
    Cost of Revenue$0$0$26,000$0$0$0$44,000$0$0$0$28,000$0
    Gross Profit$0$0$-26,000$0$0$0$44,000$0$0$0$218,000$0
    Operating Expenses$19.30M$14.88M$12.22M$10.57M$10.26M$9.92M$8.10M$7.25M$5.93M$6.25M$5.65M$5.56M
    R&D$15.96M$11.18M$9.94M$8.45M$7.87M$7.45M$5.97M$5.22M$4.11M$4.08M$4.00M$3.96M
    SG&A$3.33M$3.70M$2.28M$2.12M$2.39M$2.47M$2.13M$2.03M$1.82M$2.18M$1.65M$1.59M
    Operating Income$-19,297,000$-14,877,000$-12,217,000$-10,572,000$-10,260,000$-9,922,000$-8,105,000$-7,255,000$-5,935,000$-6,253,000$-5,651,000$-5,560,000
    Interest Income$2.05M$1.78M$603,000$738,000$639,000$525,000$508,000$566,000$434,000$316,000$5.06M$-865,000
    Interest Expense$0$0$0$0$0$0$1.83M$32.28M$0$0$0$-425,000
    Income Before Tax$-17,250,000$-13,093,000$-11,614,000$-9,834,000$-7,609,000$15.73M$-9,939,000$-39,535,000$-3,685,000$-5,937,000$-5,249,000$-5,135,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-17,959,000$-13,692,000$-12,321,000$-10,157,000$-7,998,000$15.19M$-12,113,000$-40,217,000$-4,262,000$-5,701,000$-6,653,000$-6,000,000
    EBITDA$-19,078,000$-14,865,000$-12,452,000$-11,003,000$-8,553,000$14.94M$-10,674,000$-40,604,000$-4,322,000$-6,381,000$-5,750,000$-5,775,000
    EBIT$-19,297,000$-14,877,000$-12,217,000$-10,572,000$-8,248,000$15.21M$-10,452,000$-40,101,000$-4,119,000$-6,253,000$-5,651,000$-5,560,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CRVS

    News

    Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)?

    Corvus Pharmaceuticals (CRVS) reported significantly wider losses in Q2 2026 and for the first half of 2026, shifting from a net income to a substantial net loss. While early clinical trial data for soquelitinib in atopic dermatitis is promising and supports ongoing R&D, these widening losses raise concerns about financing risk and the company's ability to sustain its multi-trial program without eroding per-share value. Analysts hold diverse views on Corvus's future, with some projecting significant revenue and earnings by 2029, while others remain pessimistic due to increasing R&D and funding needs.

    Webull•8/25/26•
    Somewhat-Bearish

    Corvus Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CRVS

    This page provides a revenue breakdown for Corvus Pharmaceuticals, Inc. (CRVS) on the NASDAQ stock market, presented through TradingView. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment performance by source and country. The content is primarily a financial data portal rather than an analytical article.

    TradingView•8/22/26•
    Neutral

    Blue Owl Capital Holdings LP Takes Position in Corvus Pharmaceuticals, Inc. $CRVS

    Blue Owl Capital Holdings LP has acquired a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), purchasing 608,600 shares valued at approximately $9.09 million. This investment makes Corvus Pharmaceuticals the 15th largest holding in Blue Owl Capital Holdings LP's portfolio, representing about 1.4% of its total assets. The article also details other institutional investments, analyst ratings, and recent insider trading activity for Corvus Pharmaceuticals.

    MarketBeat•8/21/26•
    Somewhat-Bullish

    Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)?

    Corvus Pharmaceuticals (CRVS) reported significantly wider losses for Q2 2026, with a net loss of US$17.96 million, marking a sharp shift from prior-year net income. This increased loss highlights financing risk, despite positive early-stage clinical trial data for its drug, soquelitinib. The article emphasizes that funding for its multi-trial program could be a critical factor impacting the investment narrative, with analyst forecasts showing varied revenue and earnings expectations by 2029.

    Simply Wall Street•8/20/26•
    Somewhat-Bearish

    Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)?

    Corvus Pharmaceuticals (CRVS) reported significantly wider losses in Q2 2026 and for the first half of the year, with a net loss of US$17.96 million in Q2 compared to US$8.00 million a year prior. This shift from net income to a substantial loss highlights increased financing risk despite promising Phase 1 clinical data for soquelitinib. The article emphasizes that while early clinical data is positive, investors need to consider the company's ability to fund its multi-trial program without diluting shareholder value, with analysts projecting varied outcomes for revenue and earnings by 2029.

    Simply Wall Street•8/20/26•
    Somewhat-Bearish

    Frequently Asked Questions About CRVS

    Does CRVS pay dividends?
    Corvus Pharmaceuticals Inc (CRVS) does not currently pay a regular dividend.
    What is CRVS's market cap?
    Corvus Pharmaceuticals Inc (CRVS) has a market capitalization of $1.19B with a current stock price of $14.04.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In